---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-248711"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-05-29T21:11:12+00:00"
generated_at: "2026-05-29T21:12:30.664325+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# NMS terminates license agreement with Cardiff Oncology; Cardiff disputes termination

## Summary
- NMS sent termination notice on May 27, 2026, citing alleged material breaches of the 2017 License Agreement.
- NMS claims Cardiff failed to correct inventorship to include Dr. Barbara Valsasina on two U.S. patents and failed to use commercially reasonable efforts for onvansertib.
- Cardiff filed a lawsuit on May 19, 2026, seeking injunctive relief and declaratory judgment that it did not breach the agreement.
- Cardiff responded that the termination notice is legally ineffective and will continue to perform under the agreement.
- Dispute centers on rights to onvansertib, a key pipeline asset; potential impact on development timeline.

## SEC filing metadata
- accession: 0001193125-26-248711
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-05-29T21:11:12+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/0001193125-26-248711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/crdf-20260527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-248711
- JSON: https://secwatch.observer/filing/0001193125-26-248711.json
- Plain text: https://secwatch.observer/filing/0001193125-26-248711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.